Cargando…
Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance
Ceftriaxone has been a part of therapeutic regime for combating some of the most aggressive bacterial infections in the last few decades. However, increasing bacterial resistance towards ceftriaxone and other third generation cephalosporin antibiotics has raised serious clinical concerns especially...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622407/ https://www.ncbi.nlm.nih.gov/pubmed/34834310 http://dx.doi.org/10.3390/pharmaceutics13111896 |
_version_ | 1784605686511960064 |
---|---|
author | Alshammari, Farhan Alshammari, Bushra Moin, Afrasim Alamri, Abdulwahab Al Hagbani, Turki Alobaida, Ahmed Baker, Abu Khan, Salman Rizvi, Syed Mohd Danish |
author_facet | Alshammari, Farhan Alshammari, Bushra Moin, Afrasim Alamri, Abdulwahab Al Hagbani, Turki Alobaida, Ahmed Baker, Abu Khan, Salman Rizvi, Syed Mohd Danish |
author_sort | Alshammari, Farhan |
collection | PubMed |
description | Ceftriaxone has been a part of therapeutic regime for combating some of the most aggressive bacterial infections in the last few decades. However, increasing bacterial resistance towards ceftriaxone and other third generation cephalosporin antibiotics has raised serious clinical concerns especially due to their misuse in the COVID-19 era. Advancement in nanotechnology has converted nano-therapeutic vision into a plausible reality with better targeting and reduced drug consumption. Thus, in the present study, gold nanoparticles (GNPs) were synthesized by using ceftriaxone antibiotic that acts as a reducing as well as capping agent. Ceftriaxone-loaded GNPs (CGNPs) were initially characterized by UV-visible spectroscopy, DLS, Zeta potential, Electron microscopy and FT-IR. However, a TEM micrograph showed a uniform size of 21 ± 1 nm for the synthesized CGNPs. Further, both (CGNPs) and pure ceftriaxone were examined for their efficacy against Escherichia coli, Staphylococcus aureus, Salmonella abony and Klebsiella pneumoniae. CGNPs showed MIC(50) as 1.39, 1.6, 1.1 and 0.9 µg/mL against E. coli, S. aureus, S. abony and K. pneumoniae, respectively. Interestingly, CGNPs showed two times better efficacy when compared with pure ceftriaxone against the tested bacterial strains. Restoring the potential of unresponsive or less efficient ceftriaxone via gold nanoformulations is the most alluring concept of the whole study. Moreover, applicability of the findings from bench to bedside needs further validation. |
format | Online Article Text |
id | pubmed-8622407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86224072021-11-27 Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance Alshammari, Farhan Alshammari, Bushra Moin, Afrasim Alamri, Abdulwahab Al Hagbani, Turki Alobaida, Ahmed Baker, Abu Khan, Salman Rizvi, Syed Mohd Danish Pharmaceutics Article Ceftriaxone has been a part of therapeutic regime for combating some of the most aggressive bacterial infections in the last few decades. However, increasing bacterial resistance towards ceftriaxone and other third generation cephalosporin antibiotics has raised serious clinical concerns especially due to their misuse in the COVID-19 era. Advancement in nanotechnology has converted nano-therapeutic vision into a plausible reality with better targeting and reduced drug consumption. Thus, in the present study, gold nanoparticles (GNPs) were synthesized by using ceftriaxone antibiotic that acts as a reducing as well as capping agent. Ceftriaxone-loaded GNPs (CGNPs) were initially characterized by UV-visible spectroscopy, DLS, Zeta potential, Electron microscopy and FT-IR. However, a TEM micrograph showed a uniform size of 21 ± 1 nm for the synthesized CGNPs. Further, both (CGNPs) and pure ceftriaxone were examined for their efficacy against Escherichia coli, Staphylococcus aureus, Salmonella abony and Klebsiella pneumoniae. CGNPs showed MIC(50) as 1.39, 1.6, 1.1 and 0.9 µg/mL against E. coli, S. aureus, S. abony and K. pneumoniae, respectively. Interestingly, CGNPs showed two times better efficacy when compared with pure ceftriaxone against the tested bacterial strains. Restoring the potential of unresponsive or less efficient ceftriaxone via gold nanoformulations is the most alluring concept of the whole study. Moreover, applicability of the findings from bench to bedside needs further validation. MDPI 2021-11-08 /pmc/articles/PMC8622407/ /pubmed/34834310 http://dx.doi.org/10.3390/pharmaceutics13111896 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alshammari, Farhan Alshammari, Bushra Moin, Afrasim Alamri, Abdulwahab Al Hagbani, Turki Alobaida, Ahmed Baker, Abu Khan, Salman Rizvi, Syed Mohd Danish Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance |
title | Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance |
title_full | Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance |
title_fullStr | Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance |
title_full_unstemmed | Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance |
title_short | Ceftriaxone Mediated Synthesized Gold Nanoparticles: A Nano-Therapeutic Tool to Target Bacterial Resistance |
title_sort | ceftriaxone mediated synthesized gold nanoparticles: a nano-therapeutic tool to target bacterial resistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622407/ https://www.ncbi.nlm.nih.gov/pubmed/34834310 http://dx.doi.org/10.3390/pharmaceutics13111896 |
work_keys_str_mv | AT alshammarifarhan ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT alshammaribushra ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT moinafrasim ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT alamriabdulwahab ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT alhagbaniturki ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT alobaidaahmed ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT bakerabu ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT khansalman ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance AT rizvisyedmohddanish ceftriaxonemediatedsynthesizedgoldnanoparticlesananotherapeutictooltotargetbacterialresistance |